Immunosuppressive therapy - Revision history

Aidan: linkified

2023-06-06T18:19:44Z

linkified

2022-10-11T14:32:33Z

Specific Medications: added secukinumab details, and linked a few things

2022-03-17T01:36:08Z

2021-11-02T17:03:55Z

2020-02-28T02:36:59Z

← Older revision		Revision as of 02:36, 28 February 2020
Line 37:		Line 37:
	\|}		\|}

	[[Category:Immunocompromised ~~patients~~]]		[[Category:Immunocompromised hosts]]

2019-10-15T00:50:15Z

Specific Medications: linkified, added more about ibrutinib

← Older revision		Revision as of 00:50, 15 October 2019
Line 20:		Line 20:
	! Specific Risks		! Specific Risks
	\|-		\|-
	\| Eculizumab		\| [[Eculizumab]]
	\| C5 complement		\| C5 complement
	\| Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis		\| Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis
	\|-		\|-
	\| Rituximab		\| [[Rituximab]]
	\| CD20, on B cells		\| CD20, on B cells
	\| Long-term B cell depletion		\| Long-term B cell depletion
	\|-		\|-
	\| Natalizumab		\| [[Natalizumab]]
	\| α4-integrin, on all leukocytes except neutrophils		\| α4-integrin, on all leukocytes except neutrophils
	\| JC virus		\| JC virus
	\|-		\|-
	\| Ibrutinib		\| [[Ibrutinib]]
	\| Bruton's tyrosine kinase (BTK), on B cells		\| Bruton's tyrosine kinase (BTK), on B cells
			\| Invasive aspergillosis and other fungal infections
	\|
	\|}		\|}

2019-08-17T21:16:20Z

Specific Medications

← Older revision		Revision as of 21:16, 17 August 2019
Line 37:		Line 37:
	\|}		\|}

	[[Category:~~Immunosuppressed~~ patients]]		[[Category:Immunocompromised patients]]

2019-08-16T01:30:47Z

Specific Medications

2019-08-16T01:30:39Z

← Older revision		Revision as of 01:30, 16 August 2019
Line 1:		Line 1:
	= Immunosuppressive therapy =

	== Screening ==		== Screening ==

Line 38:		Line 36:
	\|		\|
	\|}		\|}

			[[Category:Immunosuppressed patients]]

2019-08-16T01:30:23Z

← Older revision		Revision as of 01:30, 16 August 2019
(No difference)